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ABSTRACT 14 
Background: Poultry coccidiosis is a parasitic enteric disease with a highly negative impact on 15 
chicken production. In-feed chemoprophylaxis remains the primary method of control, but the 16 
increasing ineffectiveness of anticoccidial drugs, and potential future restrictions on their use has 17 
encouraged the use of commercial live vaccines. Availability of such formulations is constrained 18 
by their production, which relies on the use of live chickens. Several experimental approaches 19 
have been taken to explore ways to reduce the complexity and cost of current anticoccidial 20 
vaccines including the use of live vectors expressing relevant Eimeria proteins. We and others 21 
have shown that vaccination with transgenic Eimeria tenella parasites expressing E. maxima 22 
Apical Membrane Antigen-1 or Immune Mapped Protein-1 (EmAMA1 and EmIMP1) partially 23 
reduces parasite replication after challenge with a low dose of E. maxima oocysts. In the present 24 
work we have reassessed the efficacy of these experimental vaccines using commercial birds 25 
reared at high stocking densities and challenged with both low and high doses of E. maxima to 26 
evaluate how well they protect chickens against the negative impacts of disease on production 27 
parameters. 28 
Methods: Populations of E. tenella parasites expressing EmAMA1 and EmIMP1 were obtained by 29 
nucleofection and propagated in chickens. Cobb500 broilers were immunised with increasing 30 
doses of transgenic oocysts and challenged two weeks later with E. maxima to quantify the effect 31 
of vaccination on parasite replication, local IFN-γ and IL-10 responses (300 oocysts), as well as 32 
impacts on intestinal lesions and body weight gain (10,000 oocysts).  33 
Results: Vaccination of chickens with E. tenella expressing EmAMA1, or admixtures of E. tenella 34 
expressing EmAMA1 or EmIMP1, was safe and induced partial protection against challenge as 35 
measured by E. maxima replication and severity of pathology.  Higher levels of protection were 36 
observed when both antigens were delivered, and was associated with a partial modification of 37 
local immune responses against E. maxima, which we hypothesise resulted in more rapid immune 38 
recognition of the challenge parasites. 39 
Conclusions: This work offers prospects for future development of multivalent anticoccidial 40 
vaccines for commercial chickens. Efforts should now be focused on the discovery of additional 41 
antigens for incorporation into such vaccines. 42 
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 47 
BACKGROUND 48 
The genus Eimeria includes a large number of species, many of which can cause the disease 49 
coccidiosis in domestic livestock. Infection results in clinical or sub-clinical enteritis, typically self-50 
limiting, but often with a negative impact on key production parameters [1]. Current intensive 51 
husbandry practices in poultry production systems provide an ideal environment for Eimeria 52 
transmission, transforming coccidiosis into a major problem that has been associated with annual 53 
global costs in excess of £2 billion [1-3]. Management of variables such as poultry stocking 54 
density, quality of housing and ventilation can reduce Eimeria transmission, but additional 55 
anticoccidial control is still essential [4]. In-feed chemoprophylaxis remains the primary method 56 
of control [5], although resistance has been described among Eimeria to every drug currently 57 
available [6]. Vaccination using formulations of live Eimeria parasites offers an effective 58 
alternative to chemoprophylaxis, although the occurrence of multiple Eimeria species that infect 59 
chickens and the lack of cross-protective immunity between them requires vaccines to include 60 
lines of most, if not all Eimeria species [4]. The expansion of ‘no antibiotics, ever’ production 61 
systems has encouraged increased use of non-attenuated, wild-type vaccines in countries such 62 
as the USA, but uptake of safer, live-attenuated vaccines remains limited to the minority layer 63 
and breeder sectors in most countries. Availability of commercial live-attenuated vaccines is 64 
constrained by limitations in the capacity of their production, as each vaccine line requires 65 
independent passage through chickens, incurring costs that are significantly higher than for 66 
routine chemoprophylaxis or for non-attenuated vaccines. In the broiler sector, where profit 67 
margins are very tight, control measures are still highly dependent on the use of anticoccidial 68 
drugs, but these are increasingly ineffective or may become restricted in the near future [4, 7]. 69 
Therefore, there is an urgent need to reduce the cost and improve the availability of anticoccidial 70 
vaccine formulations to make them more attractive for this sector. 71 
To date several Eimeria proteins with relevant roles in host/parasite interaction have been tested 72 
as anticoccidial vaccines in diverse formulations, with varying efficacies [4, 8, 9]. Many of these 73 
antigens have not been developed further as vaccines, in part because they have not met what 74 
has been regarded as sufficient immune protection against challenge and/or because of the need 75 
for multiple rounds of vaccination. However, several studies have achieved levels of immune 76 
protection approaching those reported for the ionophores and for live vaccines when they were 77 
first developed (e.g. an ~60-90% reduction in parasite replication). Both of these well-established 78 
methods for controlling coccidiosis work so well because they allow low levels of Eimeria 79 
replication to continue, thus providing natural boosting of protective immunity as the parasites 80 
that escape the effects of treatment re-cycle through the chickens [8, 10]. On this basis, we have 81 
hypothesised that the use of live replicating vector systems expressing previously tested Eimeria 82 
antigens could work well for automated single-shot anticoccidial vaccine delivery, despite 83 
conferring less than complete protection against challenge. Following this hypothesis, we and 84 
others have recently shown that Eimeria tenella parasites can be used as a vector to express and 85 
deliver the protein Apical Membrane Antigen 1 from Eimeria maxima (EmAMA1), and that 86 
vaccination with such parasites was sufficient to induce significant partial protection against 87 
challenge with E. maxima oocysts [11]. Similar results were reported with E. tenella parasites 88 
expressing Immune Mapped Protein-1 from E. maxima (EmIMP1) [12], and more recently with a 89 
combination of EmAMA1 and EmIMP1-expressing parasites [13]. However, these studies were 90 
performed in inbred chicken lines kept in wire-floor cages and challenged with low parasite doses, 91 
so the data cannot be directly related to a farm setting where outbred chickens are repeatedly 92 
exposed to recycling vaccine parasites as well as to higher challenge doses of virulent wild type 93 
oocysts. Alone, low-dose challenges are not suitable for evaluation of factors relevant to a 94 
commercial perspective such as protection against intestinal damage and body weight gain. 95 
The present study aimed to evaluate the suitability of E. tenella parasites expressing EmAMA1 or 96 
EmIMP1 proteins to induce significant levels of cross protection against E. maxima under 97 
commercial conditions. For this purpose, Cobb500 broiler chickens were vaccinated with 98 
increasing doses of transgenic parasites to mimic natural recycling, reared in floor pens at 99 
commercial-level stocking densities, and subsequently challenged with a dose of pathogenic E. 100 
maxima oocysts (10,000) to assess vaccine efficacy in terms of lesion scores (protection against 101 
parasite-induced pathology) and body weight gain (protection against compromised growth). In 102 
an effort to correlate these parameters with levels of parasite replication, a sub-group of 103 
vaccinated broilers were challenged with a low dose of E. maxima oocysts (300) and used to 104 
quantify the effect of vaccination on local parasite burdens by quantitative PCR. Here we 105 
demonstrate that vaccination with transgenic E. tenella oocysts expressing EmAMA1 or with a 106 
mix of oocysts expressing either EmAMA1 or EmIMP1 induces a significant reduction in parasite 107 
replication, alleviates lesion scores and ameliorates reduction in body weight gain due to E. 108 
maxima challenge.  109 
 110 
METHODS 111 
Parasite passage 112 
Four weeks old Lohmann Selected Leghorn (LSL) chickens reared under specific pathogen-free 113 
conditions were used to propagate oocysts of the Wisconsin (Wis) strain of E. tenella and the 114 
Weybridge (W) strain of E. maxima as described by others [14]. Standard methods were used to 115 
recover and sporulate oocysts, and to purify sporozoites through nylon wool and DE-52 columns 116 
[15][16].  117 
 118 
Preparation of transgenic E. tenella Wis parasites expressing EmAMA1 and EmIMP1 119 
Eimeria tenella Wis parasites expressing EmAMA1 (termed Et[EmAMA1]) and parasites 120 
expressing only delivery signals (Et[GPI], empty vector) were used as previously described [11, 121 
17]. Similar procedures were carried out to obtain E. tenella parasites expressing EmIMP1. Briefly, 122 
the EmIMP1 coding sequence (GenBank: KP642747.1) was amplified from the pET32b-EmIMP1 123 
plasmid [18] and flanked with XbaI restriction sites by PCR using Platinum Taq DNA Polymerase 124 
High Fidelity® (Invitrogen) with the following primers: GCTCTAGAGGGGCCGCTTGCGGGAAA and 125 
GCTCTAGAATCTTGCGACACTTTAGT (Sigma–Aldrich). The EmIMP1 sequence was subsequently 126 
cloned into the XbaI site of the core construct used for E. tenella transfection, which contains (i) 127 
the mCitrine reporter and (ii) the mCherry reporter, preceded by the XbaI restriction site and 128 
flanked with the signal peptide of the EtMIC2 protein (SP2), and the glycosylphosphatidylinositol 129 
anchor of the EtSAG1 protein (GPI) [17]. Additionally, a plasmid carrying the mutant Toxoplasma 130 
gondii dihydrofolate reductase–thymidylate synthase (DHFR-TSm2m3) gene that confers 131 
resistance to pyrimethamine was also prepared for co-transfection [19]. Final plasmids were 132 
prepared for transfection using a Midi Prep Kit (Qiagen), digested for linearisation with PsiI (New 133 
England BioLabs), precipitated in ethanol-sodium acetate and quantified by NanoDrop (Thermo 134 
Scientific). A total of 1 × 106 freshly hatched E. tenella Wis sporozoites were transfected in 135 
duplicate with 12 µg (EmIMP1) and 4 µg (DHFR-TSm2m3) of PsiI-digested plasmids together with 136 
6 U of PsiI in Lonza buffer P3 using the programme EO114 of the Nucleofector 4D (Lonza). After 137 
shock, parasites were left for 20 min at room temperature in Roswell Park Memorial Institute 138 
(RPMI) medium (Sigma–Aldrich), pooled and used to infect two four-week old LSL chickens by the 139 
cloaca (0.75 × 106 sporozoites/bird). One day after infection, birds were in-feed supplemented 140 
with pyrimethamine for 6 days (150 ppm, Sigma–Aldrich) [19]. Seven days after infection, oocysts 141 
were harvested, sporulated and used for subsequent in vivo passage after population enrichment 142 
for fluorescent parasites by fluorescence-activated cell sorting (FACS) (FACS Aria III, BD) [20]. 143 
Transcription of the EmIMP1 gene was confirmed using transgenic populations by reverse 144 
transcription (RT) PCR with the primers (5’-3’): CATTCACCTTACACCACTTTG (Fw_EmIMP1-int, 145 
which anneals to the residues 692-712 of the EmIMP1 coding sequence) and 146 
ATGGTCTTCTTCTGCATTACG (Rv_mCherry-int, which anneals to the residues 423-443 of the 147 
mCherry coding sequence). For this purpose, total RNA was extracted from populations of 148 
transfected oocysts using the TRIzol® reagent (Invitrogen), and complementary DNA (cDNA) was 149 
generated using SuperScript II® reverse transcriptase and random hexamer primers (Invitrogen) 150 
as previously described [20]. The absence of genomic DNA contamination was confirmed by PCR 151 
targeting the E. tenella actin locus with primers that amplify a region coded between two adjacent 152 
exons as described earlier [11]. Expression of the EmIMP1 protein in transgenic parasites was 153 
confirmed by fluorescent microscopy through detection of the mCherry tag with a SP5 confocal 154 
microscope (Leica Microsystems). Image processing was performed using ImageJ software (NCBI, 155 
http://rsb.info.nih.gov/ij/). 156 
 157 
In vivo immunisation trial of E. tenella Wis parasites expressing EmAMA1 and EmIMP1 158 
A total of 144 Cobb500 broiler chicks (P.D. Hook hatcheries) vaccinated against infectious 159 
bronchitis virus (IB H120 vaccine) were purchased at day of hatch (day 0), weighed and distributed 160 
evenly into six different groups of 24 in independent wire-floored cages (Table 1). In order to 161 
mimic parasite recycling and ensure solid immunity (the so-called trickle infection, [21]), chicks 162 
from groups 3 to 6 were immunised by oral gavage with 100, 500 and 3,000 sporulated oocysts 163 
at days 2, 8 and 14 of age, respectively; chicks from groups 1 to 2 were inoculated with sterile 164 
water (Table 1). At days 10, 16 and 22 (8 days after each immunisation), faecal samples were 165 
randomly collected from the bottom of all cages to confirm cycling of vaccine lines by oocyst 166 
flotation [14]. Parallel analyses also confirmed that groups 1 and 2 remained non-infected during 167 
the same period. At 15 days of age, 18 out of 24 birds from each group were transferred to floor 168 
pens at high stocking densities (~650 cm2/bird), whereas 6 birds were kept in the original cages. 169 
At 29 days of age, 15 days after the last immunisation, birds from groups 2 to 6 were challenged 170 
with freshly harvested E. maxima W oocysts (1 month-old). Two different challenge doses were 171 
employed: birds kept in cages (n = 6/group) were challenged with 300 oocysts in order to quantify 172 
the effect of vaccination on parasite replication; birds kept in floor pens (n = 18/group) were 173 
infected with 10,000 oocysts to assess if vaccination was able to protect against compromised 174 
body weight gain and development of intestinal lesions; all birds from group 1 were dosed with 175 
sterile water. At day 35, 6 days after challenge, all birds kept in cages and infected with 300 176 
oocyst/bird were culled by cervical dislocation and the middle section of the intestine (~5 cm 177 
around Meckel’s diverticulum, representing the terminal jejunum and proximal ileum) was 178 
collected and preserved in RNAlater at -20ºC (ThermoFisher) until further analysis. On the same 179 
day, 7 out of 18 birds kept in floor pens and infected with 10,000 oocysts/bird were also culled to 180 
determine intestinal lesion scores following standard procedures [22]. In order to quantify body 181 
weight gains, the remaining birds (11 birds/group; 10,000 oocysts/bird) were kept in floor pens 182 
until 41 days of age, 12 days after challenge.  183 
Chickens from all groups were weighed throughout the experiment at 2 (before first vaccination), 184 
29 (before challenge), 35 (6 days after challenge) and 41 days of age (12 days after challenge). 185 
Body weight gains (BWG) were calculated as follows: %BWG = [(Final weight – initial 186 
weight)/(Initial weight)] × 100. Water and anticoccidial-free feed (baby chick crumbs, SmallHolder 187 
range) were provided ad libitum throughout the trial. 188 
Data were analysed using GraphPad Prism (version 7.02). Data normality was confirmed with the 189 
Shapiro-Wilk test. One way ANOVA with a Tukey’s post hoc test was used to compare BWG and 190 
parasite replication values. Kruskal-Wallis with a Dunn’s post hoc test was performed to analyse 191 
differences in lesion scores. 192 
 193 
DNA and RNA extractions 194 
Intestinal samples from all chickens challenged with 300 oocysts were removed from RNAlater 195 
solution, weighed and disrupted with the TissueRuptor homogenizer (Qiagen) in RLT plus lysis 196 
buffer (Qiagen) supplemented with 1% 2-mercaptoethanol (Sigma-Aldrich) at a ratio of 600 µl 197 
buffer per mg of tissue. A total of 30 mg of homogenate (~450 µl) were further homogenised 198 
using QIAshredder columns (Qiagen) and subsequently employed for simultaneous purification 199 
of DNA and RNA using the AllPrep DNA/RNA Mini Kit (Qiagen) following the manufacturer’s 200 
guidelines. DNA and RNA quality was checked by agarose gel electrophoresis and using a 201 
NanoDrop Spectrophotometer (Thermo Scientific). 202 
 203 
Quantification of E. maxima replication 204 
Plasmids harbouring fragments of the E. maxima MIC1 (EmMIC1) and the chicken beta-actin 205 
(GgACTb) genes were used as single copy template positive controls [23, 24]. The pGEMT-206 
EmMIC1 plasmid was obtained from a previous study [23], whereas the pGEMT-GdACTb was 207 
obtained as follows: a 958 bp fragment of the GdACTb genomic sequence was amplified by PCR 208 
from chicken genomic DNA using the Platinum Taq DNA Polymerase High Fidelity® (Invitrogen) 209 
and the primers CTAGAGGAGCAGAGAAGCCTCTTA and CTAGAGGAGCAGAGAAGCCTCTTA 210 
(derived from Accession Number X00182.1, purchased from Sigma-Aldrich). The PCR product was 211 
cloned using the pGEM®-T Easy vector system (Promega), propagated in E. coli XL1-Blue 212 
competent cells (Stratagene), purified using the QIAprep Spin Miniprep kit (Qiagen), and 213 
sequenced (GATC Biotech). Ten-fold dilution series representing 106 to 100 copies of each plasmid 214 
were prepared using glycogen as a carrier (final concentration of 33 μg/ml, Thermo Scientific) as 215 
described previously [23, 24].  216 
Quantitative real-time PCR (q-PCR) was performed as previously described [24] using the primers 217 
listed in Table 2. All the reactions were conducted employing white hard-shell® 96-well PCR plates 218 
and the CFX96 Touch® Real-Time PCR Detection System (Bio-Rad Laboratories). Intestinal DNA 219 
samples were amplified in triplicate in a 20 μl-reaction containing 1 μl of total gDNA, 300 nM of 220 
each primer, 10 μl of SsoFast™ EvaGreen® Supermix (Bio-Rad Laboratories), and 8.5 μl of 221 
DNase/RNase free water (ThermoFisher). Cycling conditions consisted of 95 °C for 2 min, followed 222 
by 40 cycles of 95 °C for 15 sec and 60 °C for 30 sec with a subsequent melt analysis of 65 °C–95 223 
°C at increments of 0.5 °C/0.5 sec. Each assay included the relevant plasmid standards and no 224 
template controls. The number of genomes from the host (GdACTb target) and the E. maxima 225 
parasites (EmMIC1 target) were estimated by comparison with the plasmid standard series. 226 
Triplicate data arising from each test sample were averaged and standardised by comparison with 227 
host genome concentration as E. maxima genomes/Host genomes ratio. Data normality was 228 
confirmed with the Shapiro-Wilk test, and subsequently analysed by one-way ANOVA with a 229 
Tukey’s post hoc test using GraphPad Prism (version 7.02). 230 
 231 
Quantification of local IFN-γ and IL-10 expression 232 
Transcription of IFN-γ and IL-10 was analysed by RT-q-PCR as an indication of expression as 233 
previously described [25] using RNA extracted from intestinal samples (see above). Briefly, a total 234 
of 1 µg RNA was used to synthesise complementary DNA (cDNA) using the iScriptTM cDNA 235 
Synthesis Kit (Bio-Rad Laboratories) as indicated by the manufacturer. Synthesized cDNA was 236 
diluted in DNase/RNase-Free Water as follows: 1:100 for 28S rRNA quantification, 1:5 for IFN-γ 237 
quantification, and no dilution for IL-10 transcripts.  238 
RT-q-PCR reaction mixture was prepared with 1 µL of cDNA, 500 nM of each primer (Table 2), 5 239 
µL of 2X SsoFastTM EvaGreen® Supermix (Bio-Rad Laboratories), and 3 µL of DNase/RNase-Free 240 
Water in a final volume of 10 µL per reaction. Ten-fold dilution series for target genes (28S rRNA, 241 
IFN-γ and IL-10) were prepared from a pool of cDNA samples obtained from all analysed chickens. 242 
All samples and standard points were analysed in duplicate with pertinent non-template controls 243 
under the following cycling conditions: 95 °C for 2 min, followed by 40 cycles of 95 °C for 15 sec 244 
and 60 °C for 30 sec with a subsequent melt analysis of 65 °C–95 °C at increments of 0.5 °C/0.5 245 
sec. Data were normalised using the 28S rRNA target, represented as corrected 40-Ct values. For 246 
statistical analyses, data normality was confirmed with the Shapiro-Wilk test and compared by 247 
one-way ANOVA with a Tukey’s post hoc test using GraphPad Prism (version 7.02). Two-tailed 248 
Pearson correlation coefficients between IFN-γ and IL-10 expression levels and parasite 249 
replication scores were also calculated using the same software.  250 
 251 
RESULTS 252 
Transcription and expression of EmIMP1 in transgenic E. tenella parasites 253 
Transgenic parasites expressing the EmIMP1 protein were stabilized by four successive in vivo 254 
passages under pyrimethamine selection followed by FACS enrichment of mCitrine expressing 255 
parasites. This resulted in 37% of the population expressing both reporters (mCitrine and 256 
mCherry, fused to EmIMP1; Fig. 1a) with efficiencies of FACS recovery close to 96%. EmIMP1 257 
mRNA transcription was confirmed by RT-PCR in stabilized populations in the absence of gDNA 258 
contamination (Fig. 1b). EmIMP1 protein expression was indicated by detection of the EmIMP1-259 
mCherry fusion protein by fluorescence microscopy, which was secreted into the sporocyst cavity 260 
and anchored onto the sporozoite surface as expected (Fig. 1c) [11, 17]. 261 
 262 
 263 
Vaccine safety 264 
Individual body weights were recorded before vaccination (2 days of age) and before challenge 265 
(29 days of age). Statistical analysis of average body weights at day 2 demonstrated that chicks 266 
were evenly distributed between groups (p=0.5441, ANOVA). Analysis of BWG from 2 to 29 days 267 
of age showed that vaccination with live transgenic E. tenella parasites was not detrimental in 268 
terms of growth, as all groups performed equally (p=0.1063, Kruskal-Wallis). Viability of vaccine 269 
lines was confirmed by faecal flotations. Faeces collected from the bottom of all cages 8 days 270 
after each immunisation displayed varying numbers of non-sporulated oocysts, confirming that 271 
vaccine lines were cycling (data not shown). In all the analyses, non-vaccinated birds remained 272 
uninfected. 273 
 274 
Effect of vaccination on parasite replication and local immune responses 275 
In order to assess the efficacy of vaccination after a deliberately low challenge, replication of E. 276 
maxima W parasites was quantified by q-PCR in DNA samples extracted from the mid-point of the 277 
intestine [26]. Non-vaccinated and non-challenged birds (H2O-H2O), together with birds 278 
vaccinated and challenged with E. maxima W (Emax-Emax), did not display any evidence of 279 
parasite replication. On the contrary, non-vaccinated and challenged birds (H2O-Emax), and birds 280 
vaccinated with the empty vector (Et[GPI]-Emax) displayed the highest replication scores. 281 
Chickens vaccinated with Et[EmAMA1] (Et[A]-Emax) and the combination of Et[EmAMA1] and 282 
Et[EmIMP1] parasites (Et[A+I]-Emax) displayed a significant reduction in parasite replication 283 
compared to the non-vaccinated and challenged group (H2O-Emax), and to the group vaccinated 284 
with the empty vector (Et[GPI]-Emax) (p < 0.0001, ANOVA) (Fig. 2a). This reduction was more 285 
pronounced in the Et[EmAMA1] + Et[EmIMP1] group, where parasite replication was also 286 
significantly lower than that of the group vaccinated with Et[EmAMA1] alone (p = 0.0001, ANOVA) 287 
(Fig. 2a). While differences observed in parasite replication did not have any impact on body 288 
weight gains from 29 to 35 days of age (before challenge and 6 days post-challenge) in any groups 289 
in these low dose challenged chickens (p = 0.3803, Kruskal-Wallis), birds from both vaccinated 290 
groups displayed lower lesion scores than those non-vaccinated or vaccinated with the empty 291 
vector, although no statistical differences were found (p = 0.2360, Kruskal-Wallis) (Fig. 2b). As 292 
expected, the low challenge dose used to quantify parasite replication was not adequate to 293 
induce differences in BWG or lesion scores.  294 
Intestinal samples were also used to analyse local transcription levels of IFN-γ and IL-10 by q-PCR 295 
after challenge. Overall, higher differences were observed in IFN-γ levels between groups: the 296 
highest IFN-γ levels were observed in non-vaccinated birds (H2O-Emax) and in those vaccinated 297 
with the empty vector (Et[GPI]-Emax), illustrating a typical primary response against E. maxima 298 
W. By contrast, birds vaccinated with E. maxima W (Emax-Emax) did not mount an IFN-γ response 299 
after homologous challenge, indicating a secondary response against homologous challenge. 300 
Interestingly, birds vaccinated with the Et[EmAMA1] + Et[EmIMP1] combination (Et[A+I]-Emax) 301 
showed lower IFN-γ levels compared with the non-vaccinated and challenged group (H2O-Emax), 302 
suggesting a secondary-type response against E. maxima W (p = 0.0289, ANOVA). Birds 303 
vaccinated with Et[EmAMA1] alone (Et[A]-Emax) did not show clear differences with any control 304 
group (H2O-H2O, H2O-Emax, Emax-Emax or Et[GPI]-Emax), suggesting an intermediate primary-305 
secondary response against the parasite (Fig. 2c). Regarding IL-10, mRNA levels were increased 306 
after E. maxima W challenge in non-vaccinated birds (H2O-Emax) and chickens receiving the 307 
empty vector (Et[GPI]-Emax) compared to birds vaccinated and challenged with E. maxima W 308 
(Emax-Emax) (p < 0.05, ANOVA). This was indicative of primary and secondary responses against 309 
E. maxima W, respectively. Interestingly, no statistical differences were found with any 310 
vaccinated group, which could also indicate an intermediate response in those animals (Fig. 2c). 311 
In addition, when we performed correlation tests, they showed a positive correlation for both 312 
IFN-γ (r = 0.6817, p < 0.0001, two-tailed Pearson test) and IL-10 (r = 0.6175, p < 0.0001, two-tailed 313 
Pearson test) with parasite replication scores. 314 
 315 
Effect of vaccination on production scores and pathology 316 
A total of 90 birds (18 per group) were challenged with a high dose of E. maxima W (10,000 317 
oocysts) to assess the efficacy of vaccination with transgenic parasites against development of 318 
local lesions (7 birds per group, determined 6 days after challenge) and against reduced body 319 
weight gain (11 birds per group, calculated 11 days after challenge). Eighteen additional birds 320 
were not challenged and served as negative controls.  321 
The distribution of lesion scores among groups is shown in Fig. 3a. Vaccination with E. maxima W 322 
parasites (Emax-Emax) yielded the best protection results, showing no statistical differences with 323 
the non-challenged birds (H2O-H2O) (p > 0.05, Kruskal-Wallis) as only two out of seven animals 324 
showed lesions, both of which were very mild. Conversely, non-vaccinated birds (H2O-Emax) and 325 
those immunised with the empty vector (Et[GPI]-Emax) displayed the highest lesion scores, 326 
showing clear differences with the non-challenged birds (H2O-H2O) (p < 0.005, Kruskal-Wallis). 327 
Vaccination with Et[EmAMA1] alone (Et[A]-Emax) or the Et[EmAMA1] + Et[EmIMP1] combination 328 
(Et[A+I]-Emax) reduced the average lesion scores but statistically there were no differences 329 
between these and either the non-protected (H2O-Emax and Et[GPI]-Emax groups) or the ‘fully’ 330 
protected  (Emax-Emax) groups (p > 0.05, Kruskal-Wallis). Interestingly, average lesion scores 331 
were lower in the group vaccinated with Et[EmAMA1] + Et[EmIMP1] parasites, with the majority 332 
of birds showing lesion scores under 2; however, these differences were not significant (p > 0.005, 333 
Kruskal-Wallis). 334 
Percentages of BWG are displayed in Fig. 3b. Similarly to the lesion scores, chickens vaccinated 335 
with E. maxima W oocysts (Emax-Emax) performed as well as non-challenged birds (H2O-H2O) (p 336 
> 0.05, ANOVA), whereas non-vaccinated and challenged birds (H2O-Emax) and birds vaccinated 337 
with the empty vector (Et[GPI]-Emax) showed significant reductions in BWG (p < 0.05, ANOVA). 338 
Neither Et[EmAMA1] nor Et[EmAMA1] + Et[EmIMP1]-vaccinated groups showed statistical 339 
differences to the ‘non-protected’ groups (H2O-Emax and Et[GPI]-Emax), suggesting that 340 
vaccination was insufficient to prevent body weight losses (p > 0.05, ANOVA). However birds 341 
vaccinated with Et[EmAMA1] did not display any significant difference from the ‘fully protected’ 342 
animals (Emax-Emax) and the non-challenged birds (H2O-H2O) either, indicating that this 343 
formulation was able to induce partial levels of protection against reduced body weight gain (p > 344 
0.05, ANOVA). Since variability in the H2O-Emax group was very high, removal of the outlier 345 
individuals for supplementary statistical analysis resulted in three clear clusters of animals: ‘fully 346 
protected’ (H2O-H2O and Emax-Emax), ‘non-protected’ (H2O-Emax) and ‘partially protected’ 347 
(Et[GPI]-Emax, Et[A]-Emax and Et[A+I]-Emax) (p < 0.05, ANOVA) (data not shown). 348 
 349 
DISCUSSION 350 
Live anticoccidial vaccines are highly effective for control of poultry coccidiosis caused by Eimeria, 351 
but their price and limited availability preclude broad usage across much of the broiler sector 352 
where anticoccidial drugs are still dominant. Anticoccidial vaccine candidates are available as the 353 
basis of future subunit vaccines, but strategies for effective and scalable delivery are yet to be 354 
established. In response, studies have been focused on the development and validation of 355 
genetically modified E. tenella parasites expressing antigens from other Eimeria species with the 356 
aim of (i) establishing an automated single-shot delivery system suitable for intensive farming 357 
systems, (ii) inducing significant levels of immune protection against different Eimeria species, 358 
and ultimately (iii) simplifying current vaccine formulations from 7-8 parasite lines to a small 359 
number of transgenic Eimeria populations expressing antigens from different Eimeria species. We 360 
and others have previously demonstrated that E. tenella can express exogenous reporter genes 361 
[27, 28], antigens of other poultry pathogens [20, 29], and also vaccine candidates from other 362 
Eimeria species such as E. maxima [11-13]. These later publications have highlighted the efficacy 363 
of E. tenella parasites expressing EmAMA1 and EmIMP1 as vaccines that can protect against E. 364 
maxima challenge of inbred chickens. For this study we aimed to reassess the efficacy of these 365 
vaccines in a more commercially relevant scenario of poultry coccidiosis, mimicking an intensive 366 
farming system where broiler breeds are reared at high densities and risk exposure to high levels 367 
of Eimeria oocysts. Knowing in advance that these vaccines were not able to induce sterile 368 
protective immunity, we focused our interest on determining if vaccination was sufficient to 369 
prevent reduced body weight gain and/or severe gut pathology at levels that could be acceptable 370 
from a commercial perspective.  371 
Prior to E. maxima challenge growth performance was comparable between vaccinated and non-372 
vaccinated chickens, supporting our previous findings with regards to vaccine safety [11]. 373 
Notably, vaccination with Et[EmAMA1] or with the combination of Et[EmAMA1] and Et[EmIMP1] 374 
conferred significant protection against E. maxima replication, with chickens displaying a 375 
significantly reduced E. maxima/host genomes ratio, especially in those receiving the bivalent 376 
vaccine. These results confirm observations using inbred chicken lines where vaccination with 377 
Et[EmAMA1], Et[EmIMP1], or Et[EmAMA1] plus Et[EmIMP1] significantly reduced total oocyst 378 
outputs after challenge with low E. maxima doses [11-13, 18].  379 
Vaccination with transgenic E. tenella that expressed E. maxima antigens modified the host 380 
immune response against subsequent E. maxima challenge. It is well established that resistance 381 
to primary Eimeria infection is mediated by IFN-γ [30-32]. In the case of E. maxima, previous 382 
studies have described the occurrence of different local immune responses after challenge, with 383 
IFN-γ mRNA levels peaking after the first infection and being almost unaffected by subsequent 384 
infections [33]. We observed the same response in Emax-Emax chickens after secondary infection 385 
(low IFN-γ mRNA levels, similar to those observed in H2O-H2O chickens) compared to primary 386 
infection in H2O-Emax birds (high IFN-γ mRNA levels). However, birds vaccinated with transgenic 387 
parasites (Et[A]-Emax and Et[A+I]-Emax) showed intermediate IFN-γ mRNA responses, indicating 388 
the development of a certain degree of immune memory against E. maxima. This finding is 389 
supported by a previous study, where vaccination with Et[EmAMA1] + Et[EmIMP1] was enough 390 
to induce specific IFN-γ responses after stimulation of PBMCs with E. maxima extracts [13]. We 391 
also measured IL-10 levels in the intestine since this cytokine has been correlated with 392 
susceptibility to E. maxima infection, possibly through inhibition of IFN-γ synthesis [34, 35]. Local 393 
IL-10 mRNA levels showed a pattern similar to that described for IFN-γ, with low levels of 394 
expression in the Emax-Emax group, high levels in the H2O-Emax group, and intermediate levels 395 
in the Et[A]-Emax and Et[A+I]-Emax groups. This is in agreement with our previous study, where 396 
IL-10 serum levels were significantly lower in birds vaccinated with transgenic Et[EmAMA1] 397 
parasites after E. maxima challenge compared to non-vaccinated and challenged birds [11]. This 398 
reduction in intestinal IL-10 levels could favour the development of IFN-γ-mediated responses, 399 
with effective immune killing of replicating parasites and a consequent reduction of oocyst 400 
shedding as previously suggested [34, 35]. 401 
It has previously been shown that (i) quantification of oocyst shedding following a low dose 402 
challenge is not an appropriate indicator of protection against clinical coccidiosis (normally 403 
induced by significantly higher numbers of parasites), and (ii) that infection with higher doses 404 
would increase oocyst shedding with little or no correlation to growth performance [36]. For this 405 
reason, we also challenged a group of chickens with higher doses of sporulated E. maxima oocysts 406 
(10,000 per bird) and culled them at two different time-points to assess the effect of vaccination 407 
on gut lesions (6 days after challenge) and BWG (12 days after challenge). Severity of gut lesions 408 
was partially reduced by vaccination with Et[EmAMA1], and this effect was slightly better when 409 
Et[EmAMA1] and Et[EmIMP1] parasites were combined. Chickens vaccinated with any of the 410 
formulations displayed intermediate lesion scores that did not differ from those observed in the 411 
‘fully protected’ or ‘unprotected’ control groups. This phenomenon might be an effect of the 412 
enhanced IFN-γ responses triggered by vaccination as suggested for E. tenella infections [37]. 413 
While a reduction in gut pathology following challenge can be taken as a proof of protection by 414 
anticoccidial vaccines, it has been demonstrated that the use of lesion scores alone may under 415 
estimate efficacy since commercially vaccinated chickens with lesions are able to perform as well 416 
as birds with no lesions in terms of BWG [38, 39].  417 
Performance parameters such as BWG remain a key accepted criterion to evidence effective 418 
development of protective immune responses in vaccinated chickens after high-level Eimeria 419 
challenge [36]. In our trial, only vaccination with Et[EmAMA1] parasites was able to induce partial 420 
levels of protection, with birds showing intermediate performance compared to the ‘fully 421 
protected’ and ‘unprotected’ control groups. We observed the same effect in a previous pilot trial 422 
where Cobb500 birds were vaccinated once with 100 Et[EmAMA1] oocysts (data not shown). 423 
Similarly, vaccination with AMA1 from varying Eimeria species using diverse vaccine platforms 424 
has been shown to be able to confer partial levels of protection against reduced weight gain after 425 
high-level homologous parasite challenge [40-42]. Intriguingly, and despite evidence that 426 
vaccination using IMP1 can induce protection in terms of BWG [43-45], we did not observe any 427 
notable protection in growth of chickens vaccinated with Et[EmAMA1] + Et[EmIMP1]. Differences 428 
in growth performance between the Et[EmAMA1] and Et[EmAMA1] + Et[EmIMP1] vaccinated 429 
groups may be a consequence of the differential antigen load of each formulation, since the 430 
Et[EmAMA1] + Et[EmIMP1] group was immunised with half the number of EmAMA1-expressing 431 
parasites compared to the Et[EmAMA1] group. This suggests that antigen load should be always 432 
considered as it may influence the presence or absence of a protective response, at least in terms 433 
of BWG. However, since the parasite populations used for immunisation were not clonal it is 434 
extremely difficult to determine the exact quantity of transprotein that was effectively delivered 435 
in each vaccine formulation, even employing indirect methods such as the q-PCR described earlier 436 
[15]. It is also worth highlighting that the variation observed in BWG in the non-vaccinated and 437 
challenged control group could have interfered with data interpretation, since performance of a 438 
quarter of those chickens was comparable to birds from the non-challenged (H2O-H2O) and the 439 
vaccinated (Emax-Emax) control groups. This variation likely reflects individual differences in 440 
susceptibility to coccidiosis, mainly attributed to breeding programs in hybrid commercial chicken 441 
lines [46, 47]. For this reason, broilers should not be used to test vaccine efficacy of new 442 
formulations in the first instance [36]. 443 
 444 
CONCLUSIONS 445 
Here we confirm that vaccination of commercial broiler chickens with E. tenella parasites 446 
expressing EmAMA1, or the combination EmAMA1 + EmIMP1, is able to significantly reduce E. 447 
maxima replication following subsequent challenge. The level of protection was higher when 448 
both antigens were combined. We also show that vaccination using these transgenic parasite 449 
lines partly modifies host immune responses against heterologous E. maxima challenge, at least 450 
in terms of local IFN-γ and IL-10 responses, which could lead to earlier immune recognition and 451 
reduction of parasite replication. Vaccination with both formulations also reduced the severity of 452 
pathology after high level challenge, with Et[EmAMA1] + Et[EmIMP1] showing the lowest average 453 
lesion scores correlated with a reduction in parasite replication. Nonetheless, only chickens 454 
vaccinated with Et[EmAMA1] parasites were partially protected against reduced body weight 455 
gain, although the high levels of variation observed in the non-vaccinated and challenged control 456 
groups prevented robust comparison. Overall the results of this work offer good prospects for 457 
future development of multivalent anticoccidial vaccines for commercial systems using 458 
appropriate vaccine candidates. Thus, our efforts should now be focused on the discovery of 459 
optimal targets for vaccination, and their validation and assessment to exploit the opportunities 460 
of this toolbox.  461 
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  521 
FIGURE LEGENDS 522 
 523 
Fig. 1. Preparation of transgenic Eimeria tenella Wis parasites expressing EmIMP1. (a) Simplified 524 
representation of the plasmid used for E. tenella transfection coding for the EmIMP1 protein. 525 
Scissors represent the location of the XbaI restriction site used for transgene insertion. F and R 526 
represent the primers used to confirm transgene transcription by by reverse transcription (RT)-527 
PCR. (b) Detection of EmIMP1-mCherry transcripts in cDNA isolated from stable transgenic 528 
populations by RT-PCR. A single band of ∼0.9 kb was obtained from E. tenella populations 529 
expressing EmIMP1 (Et[EmIMP1]), but not from the wild-type vector (EtW). The construct used 530 
for parasite transfection was included as a positive control. A non-template control (NTC) was 531 
also included. (c) Detection of EmIMP1-mCherry expression by confocal microscopy. The mCitrine 532 
was expressed as a cytosolic protein and used to select transgenic parasites by flow cytometry, 533 
whereas the EmIMP1-mCherry fusion protein was secreted into the sporocyst cavity and 534 
anchored onto the sporozoite surface [17]. Bars represent 10 µm.  535 
 536 
Fig. 2. Vaccine efficacy against low E. maxima W challenge (300 oocysts/bird). (a) E. maxima W 537 
burdens quantified by q-PCR and presented as a parasite genomes per host genome ratio. Dots 538 
represent individual animals, and bars indicate average values and standard deviations. Groups 539 
marked with different letters were significantly different (p < 0.0001, ANOVA). (b) Lesion scores 540 
observed in chickens used to quantify parasite replication. Diamonds represent individual 541 
animals, and bars indicate average values and standard deviations. No differences were observed 542 
(p = 0.3803, Kruskal-Wallis). (c) IFN-γ and IL-10 local immune responses in the intestine from birds 543 
used to quantify parasite replication. Dots represent individual animals, and bars indicate average 544 
values and standard deviations. Groups linked with lines were significantly different (*: p < 0.05; 545 
**: 0.0001 < p < 0.05; ***: p < 0.0001, ANOVA). 546 
 547 
Fig. 3. Vaccine efficacy against high E. maxima W challenge (10,000 oocysts/bird). (a) Intestinal 548 
lesion scores from vaccinated and control chickens. Lesion scores were determined 6 days after 549 
E. maxima W challenge (35 days of age). Diamonds represent individual animals, and bars indicate 550 
average values and standard deviations. Groups marked with different letters were significantly 551 
different (p < 0.05, Kruskal-Wallis). (b) Percentage body weight gains (BWG) from vaccinated and 552 
control chickens 12 days after challenge. BWG was calculated from day of challenge (29 days of 553 
age) to day of cull (41 days of age). Dots represent individual animals, and bars indicate average 554 
values and standard deviations. Groups marked with different letters were significantly different 555 
(p < 0.05, ANOVA).  556 
 557 
TABLES 558 
 559 
Table 1. Experimental design for vaccine trial 560 
Group Abbreviation Vaccine 
Immunisation 
protocol 
Challenge 
(E. maxima W) 
n PR1 
(cages) 
n LS2 
(pens) 
n BWG3 
(pens) 
Day 2 Day 8 Day 14 Day 29 
Culled at 
day 35 
Culled at 
day 35 
Culled at 
day 41 
1 H2O-H2O H2O H2O H2O H2O 
H2O - 7 11 
H2O 6 - - 
2 H2O-Emax 
H2O 
(no 
protection) 
 
H2O H2O H2O 
10,000 - 7 11 
300 6 - - 
3 Emax-Emax 
E. maxima W 
(‘full’ 
protection)  
100 500 3,000 
10,000 - 7 11 
300 6 - - 
4 Et[GPI]-Emax 
Et[GPI]a, b 
(empty vector) 
100 500 3,000 
10,000 - 7 11 
300 6 - - 
5 Et[A]-Emax Et[EmAMA1]a 100 500 3,000 
10,000 - 7 11 
300 6 - - 
6 Et[A+I]-Emax 
Et[EmAMA1] + 
Et[EmIMP1]a* 
100 500 3,000 
10,000 - 7 11 
300 6 - - 
 561 
a: FACS enriched transgenic E. tenella parasites. b: E. tenella Wis parasites expressing the signal 562 
peptide of the EtMIC2 protein, and the glycosylphosphatidylinositol (GPI) anchor of the EtSAG1 563 
protein. *: equal proportions of EmAMA1 and EmIMP1-expressing parasites were used for 564 
vaccination.  565 
1: number of birds used to quantify parasite replication. 2: number of birds used to assess lesion 566 
scores. 3: number of birds used to quantify body weight gains. 567 
 568 
Table 2. Primer sequences used for q-PCR analyses 569 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) Accession No. PMID 
GgACTb GAGAAATTGTGCGTGACATCA CCTGAACCTCTCATTGCCA X00182.1 26141544 
EmMIC1 TCGTTGCATTCGACAGATTC TAGCGACTGCTCAAGGGTTT M99058 16300767 
Gg28S 
rRNA 
GGCGAAGCCAGAGGAAACT GACGACCGATTTGCACGTC AH001604 
25796577 
GgIFNγ GCTCCCGATGAACGACTTGA 
TGTAAGATGCTGAAGAGTTCA
TTCG 
GQ421600.1 
20470818 
GgIL10 CATGCTGCTGGGCCTGAA    CGTCTCCTTGATCTGCTTGATG 
NM_0010044
14 
29316981 
 570 
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